Brokerages Set Cardlytics, Inc. (NASDAQ:CDLX) Price Target at $6.42

Shares of Cardlytics, Inc. (NASDAQ:CDLX) have been given a consensus recommendation of “Hold” by the seven analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $6.42.

Several brokerages have issued reports on CDLX. Evercore ISI dropped their target price on shares of Cardlytics from $4.00 to $3.00 and set an “in-line” rating on the stock in a report on Thursday, March 13th. Lake Street Capital cut their price objective on shares of Cardlytics from $5.00 to $3.00 and set a “hold” rating on the stock in a report on Thursday, March 13th. Finally, Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a report on Thursday, March 13th.

Insider Activity at Cardlytics

In related news, CEO Amit Gupta sold 46,857 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total transaction of $159,313.80. Following the transaction, the chief executive officer now directly owns 418,637 shares of the company’s stock, valued at $1,423,365.80. This represents a 10.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Alexis Desieno sold 8,854 shares of the firm’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $3.67, for a total value of $32,494.18. Following the completion of the sale, the chief financial officer now directly owns 121,976 shares of the company’s stock, valued at approximately $447,651.92. This represents a 6.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 111,454 shares of company stock valued at $391,864 over the last 90 days. Insiders own 4.40% of the company’s stock.

Institutional Trading of Cardlytics

Several large investors have recently bought and sold shares of the stock. Tallon Kerry Patrick acquired a new stake in shares of Cardlytics during the fourth quarter worth $37,000. Atom Investors LP purchased a new position in Cardlytics in the 3rd quarter worth $33,000. ProShare Advisors LLC acquired a new stake in Cardlytics during the 4th quarter worth about $43,000. Intech Investment Management LLC purchased a new stake in Cardlytics during the 3rd quarter valued at about $47,000. Finally, Virtu Financial LLC purchased a new stake in Cardlytics in the fourth quarter valued at approximately $62,000. Hedge funds and other institutional investors own 68.10% of the company’s stock.

Cardlytics Price Performance

Shares of CDLX stock opened at $2.48 on Friday. Cardlytics has a twelve month low of $1.77 and a twelve month high of $20.52. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. The stock has a fifty day simple moving average of $2.90 and a two-hundred day simple moving average of $3.44. The stock has a market capitalization of $129.17 million, a price-to-earnings ratio of -0.41 and a beta of 1.62.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.